[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602733":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":25,"responsibleParty":75,"collaborators":18,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":18,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":18,"enrollmentInfo":88,"targetDuration":18,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continue GLP\u002FGIP medication","ACTIVE_COMPARATOR","Patient maintains dose, frequency, duration of medication prior to colonoscopy.",[13],"Drug: Continue GLP\u002FGIP",{"label":15,"type":16,"description":17,"interventionNames":18},"Hold medication","NO_INTERVENTION","Withholds prior dose of GLP-1 or GIP therapy per ASA guidance recommendations",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Continue GLP\u002FGIP","Continue GLP-1 or GIP-based therapy as prescribed prior to the procedure.",[9],[26,48,57],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Cleveland Clinic","RECRUITING","Cleveland","Florida","44195","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-81.98398,26.96173,{"lat":38,"lon":37},[41,46],{"name":42,"role":43,"phone":44,"phoneExt":18,"email":45},"Samita Garg, M.D.","CONTACT","216-444-7000","GARGS@ccf.org",{"name":42,"role":47,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":49,"geoPoint":51,"contacts":52},{"type":35,"coordinates":50},[37,38],{"lat":38,"lon":37},[53,56],{"name":54,"role":43,"phone":55,"phoneExt":18,"email":45},"Samita Garg, MD","216-444-2386",{"name":54,"role":47,"phone":18,"phoneExt":18,"email":18},{"facility":58,"status":28,"city":59,"state":30,"zip":60,"country":32,"countryCode":33,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Cleveland Clinic Weston","Weston","33331",{"type":35,"coordinates":62},[63,64],-80.39977,26.10037,{"lat":64,"lon":63},[67,71,74],{"name":68,"role":43,"phone":69,"phoneExt":18,"email":70},"Tilak Shah, M.D.","877.463.2010","SHAHT3@ccf.org",{"name":72,"role":43,"phone":18,"phoneExt":18,"email":73},"Akram Ahmad, M.D.","ahmada5@ccf.org",{"name":68,"role":47,"phone":18,"phoneExt":18,"email":18},{"type":47,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Shah,Tilak","Principal Investigator","100602733","phase-4-the-impact-of-glp-medication-on-colonoscopy-bowel-preparation-quality-100602733",false,"NCT07127354","The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality","The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patient (Age 18 years or older)\n* Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy\n* Using a GLP-1 or GIP agonist at a stable dose for at least one month\n\nExclusion Criteria:\n\n* Unable to provide informed consent, e.g., dementia\n* Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)\n* Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater:\n\n  1. Cirrhosis\n  2. Parkinson's disease\n  3. Dementia\n  4. Tricyclic antidepressant use\n  5. Opioid use\n  6. Gastroparesis\\* or suspected gastric outlet obstruction on pre-procedure imaging (\\*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy)\n  7. Previous colorectal surgery\n  8. Prior history of inadequate bowel preparation",true,"ALL","18 Years",{"count":89,"type":90},132,"ESTIMATED","INTERVENTIONAL",[93],"PHASE4","The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are:\n\n* Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation?\n* Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication?\n* Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?",[96,97],"GLP - 1","Bowel Preparation for Colonoscopy",[99,100],"GLP-1","Bowel preparation for colonoscopy","2025-12-02",{"date":103,"type":104},"2025-12-04","ACTUAL",{"date":106,"type":104},"2025-08-01",{"date":108,"type":90},"2026-08",{"name":5,"class":6},3]